Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

17.11 +0.28 (+1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,306,620
Open 17.01
Bid (Size) 16.00 (1)
Ask (Size) 17.55 (6)
Prev. Close 16.83
Today's Range 16.26 - 17.21
52wk Range 15.16 - 28.05
Shares Outstanding 161,429,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
This Biotech Looks Good With Increased M&A activity
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
Via Talk Markets
ACADIA Pharmaceuticals's Return On Capital Employed Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06... 
Via Benzinga

Performance

YTD
-29.85%
-29.85%
1 Month
-19.82%
-19.82%
3 Month
-34.57%
-34.57%
6 Month
-11.30%
-11.30%
1 Year
-22.01%
-22.01%

More News

Read More
ACADIA Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA Pharmaceuticals's Earnings Outlook
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis
Via Benzinga
Futures Flat As Yen Discombobulation Extends To Record 13th Day
Via Talk Markets
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
23 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
Why Acadia Pharma Shares Are Falling Today
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
From Acadia Pharmaceuticals Inc.
Via Business Wire
28 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Via Benzinga
Acadia: Helping With Alzheimers And Parkinsons
Via Talk Markets
Stocks And Oil Drop Following The Weak Job Report
Via Talk Markets
9 Monster Stock Market Predictions For The Week Of March 28
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.